G-CSF as prophylaxis of febrile neutropenia in SCLC

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 9, 2002, Pages 1273-1281

  Adams, Jared R ^a   Lyman, Gary H ^a   Djubegovic, Benjamin ^a   Feinglass, Joe ^a   Bennett, Charles L ^a  

^a Veteran's Administration   (United States)

Author keywords

Colony stimulating factor; Febrile neutropenia; Granulocyte colony stimulating factor; Small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; CANCER CENTER; CANCER PALLIATIVE THERAPY; COMMUNITY MEDICINE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOSIMETRY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FEMALE; HEALTH SERVICES RESEARCH; HUMAN; LUNG SMALL CELL CANCER; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREVENTION; REVIEW;

EID: 0036724307     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.9.1273     Document Type: Review

References (24)

1. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
2. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
3. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor
4. American society of clinical oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
5. Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines
6. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology
7. 2000 Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based, clinical practice guidelines
8. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: An analysis using a markov model
9. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
10. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
11. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: Meta-analysis and pharmacoeconomic evaluation
12. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer
13. Use of the hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey. For the Health Services Research Committee of ASCO
14. Use of hematopoietic colony stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology survey regarding ASCO clinical practice guidelines
15. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Oncology survey
16. A cost analysis of hematopoietic colony-stimulating factors
17. Incorporation of quality-of-life considerations into decision models for the use of colony-stimulating factors in chemotherapy patients at risk for febrile neutropenia
18. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer
19. Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): Survey results of fifteen Paris university hospitals
20. Growth factor usage patterns and outcomes in the community setting: Collection through a practice-based computerized clinical information system
21. Role of granulocyte-and granulocyte macrophage colony stimulating factors in clinical practice: Balancing clinical and economic concerns
22. Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer
23. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: e7593-a Phase III trial of the Eastern Cooperative Oncology Group
24. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer